Literature DB >> 17897185

A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis.

L Peran1, D Camuesco, M Comalada, E Bailon, A Henriksson, J Xaus, A Zarzuelo, J Galvez.   

Abstract

AIMS: The intestinal anti-inflammatory effects of three probiotics with immunomodulatory properties, Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium lactis, were evaluated and compared in the trinitrobenzenesulphonic acid (TNBS) model of rat colitis. METHODS AND
RESULTS: Colitis was induced in rats by intracolonic administration of 10 mg of TNBS dissolved in 0.25 ml of 50% ethanol. Each probiotic was administered orally (5x10(8) CFU suspended in 0.5 ml of skimmed milk) for 3 weeks, starting 2 weeks before the administration of TNBS. Colonic damage was evaluated histologically and biochemically 1 week after TNBS instillation. The results obtained revealed that all probiotics assayed showed intestinal anti-inflammatory effects, macroscopically evidenced by a significant reduction in the colonic weight/length ratio. Only B. lactis showed a lower incidence of diarrhoea in comparison with untreated rats. Biochemically, all probiotics restored colonic glutathione levels, depleted as a consequence of the oxidative stress of the inflammatory process. Bifidobacterium lactis treatment reduced colonic tumour necrosis factor (TNF)-alpha production, and inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) expression; L. acidophilus administration reduced colonic leukotriene B4 production and iNOS expression and L. casei intake was associated with a decrease in colonic COX-2 expression.
CONCLUSION: The three probiotics assayed have shown intestinal anti-inflammatory activity in the TNBS model of rat colitis, although each probiotic shows its own anti-inflammatory profile. SIGNIFICANCE AND IMPACT OF THE STUDY: These probiotics could be considered as potential adjuvants in the treatment of inflammatory bowel disease, although more studies are required in order to demonstrate their efficacy in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897185     DOI: 10.1111/j.1365-2672.2007.03302.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  37 in total

1.  Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Authors:  David Philippe; Laurent Favre; Francis Foata; Oskar Adolfsson; Genevieve Perruisseau-Carrier; Karine Vidal; Gloria Reuteler; Johanna Dayer-Schneider; Christoph Mueller; Stéphanie Blum
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action.

Authors:  Esther Swee Lan Chong
Journal:  World J Microbiol Biotechnol       Date:  2013-09-26       Impact factor: 3.312

3.  Evaluation of anti-colitic effect of lactic acid bacteria in mice by cDNA microarray analysis.

Authors:  Hoyong Lee; Young-Tae Ahn; Jung-Hee Lee; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

4.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

5.  Effects of strains of Lactococcus lactis on the production of nitric oxide and cytokines in murine macrophages.

Authors:  Chise Suzuki; Ayako Aoki-Yoshida; Hiromi Kimoto-Nira; Miho Kobayashi; Keisuke Sasaki; Koko Mizumachi
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

6.  Therapeutic effects of four strains of probiotics on experimental colitis in mice.

Authors:  Lin Lin Chen; Xue Hong Wang; Yi Cui; Guang Hui Lian; Jie Zhang; Chun Hui Ouyang; Fang Gen Lu
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

7.  Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis.

Authors:  Jung-Hee Lee; Bomi Lee; Hye-Sung Lee; Eun-Ah Bae; Hoyong Lee; Young-Tae Ahn; Kwang-Sei Lim; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

8.  Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy.

Authors:  Erika Mileti; Gianluca Matteoli; Iliyan D Iliev; Maria Rescigno
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

9.  Bifidobacterium longum HY8004 attenuates TNBS-induced colitis by inhibiting lipid peroxidation in mice.

Authors:  In-Ah Lee; Eun-Ah Bae; Jung-Hee Lee; Hoyong Lee; Young-Tae Ahn; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Inflamm Res       Date:  2009-11-01       Impact factor: 4.575

Review 10.  Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases.

Authors:  Christopher D Packey; R Balfour Sartor
Journal:  Curr Opin Infect Dis       Date:  2009-06       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.